Nurix Therapeutics, Inc. (NRIX) [Rocket]

In millions, except per share items	Nov-30-22	Nov-30-21	Nov-30-20	Nov-30-19	Nov-30-18
	8-K	10-K	10-K	10-K	S-1/A
Total revenues [+]	184.5	29.8	17.8	31.1	40.5
Royalties	184.5				40.5
Revenue growth	520.2%	66.9%	-42.7%	-23.2%
Cost of goods sold	222.5	0.0	0.0	0.0	47.2
Gross profit	-38.0	29.8	17.8	31.1	-6.7
Gross margin	-20.6%	100.0%	100.0%	100.0%	-16.5%
Selling, general and administrative [+]	38.0	31.2	16.3	8.3	6.7
General and administrative	38.0	31.2	16.3	8.3	6.7
Research and development		116.4	66.5	45.0
Other operating expenses	107.9				-3.6
EBITDA [+]		-115.1	-62.8	-19.9	-6.8
EBITDA growth	59.8%	83.3%	215.9%	194.5%
EBITDA margin	-99.7%	-386.9%	-352.4%	-63.9%	-16.7%
Depreciation and amortization		2.8	2.2	2.4	3.0
EBIT [+]	-183.9	-117.9	-65.0	-22.2	-9.7
EBIT growth	56.0%	81.4%	192.2%	128.3%
EBIT margin	-99.7%	-396.3%	-364.7%	-71.5%	-24.0%
Interest income		0.8	1.2	0.8	0.8
Interest income		0.8	1.2	0.8	0.8
Other income (expense), net	3.5
Pre-tax income	-180.4	-117.1	-63.8	-21.5	-8.9
Income taxes	0.0	0.1	-20.5	0.2	0.5
Tax rate	0.0%		32.2%
Net income	-180.4	-117.2	-43.2	-21.7	-9.4
Net margin	-97.8%	-393.9%	-242.7%	-69.7%	-23.3%

Basic EPS [+]	($3.71)	($2.73)	($2.76)	($6.59)	($3.35)
Growth	35.8%	-1.0%	-58.1%	96.9%
Diluted EPS [+]	($3.71)	($2.73)	($2.76)	($6.59)	($3.35)
Growth	35.8%	-1.0%	-58.1%	96.9%

Shares outstanding (basic) [+]	48.6	42.9	15.7	3.3	2.8
Growth	13.3%	173.7%	376.0%	16.9%
Shares outstanding (diluted) [+]	48.6	42.9	15.7	3.3	2.8
Growth	13.3%	173.7%	376.0%	16.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.